Disclosed is the use of an antibody conjugate for the preparation of a medicament for the treatment of inflammatory bowel disease (IBD) or the delivery of an immunosuppressive or anti-inflammatory molecule to sites of inflammatory bowel disease (IBD) in a patient, wherein the antibody conjugate comprises an antibody, or an antigen-binding fragment thereof, that binds the Extra Domain-A (ED-A) of fibronectin and is conjugated to an immunosuppressive or anti-inflammatory molecule such as IL-10, said antibody comprising a VH domain and a VL domain, wherein the VH domain comprises heavy chain CDR1, CDR2 and CDR3 amino acid sequences comprising the amino acid sequences of SEQ ID NOs: 1(LFT), 2(SGSGGS) and 3(STHLYL), respectively； and the VL domain comprises light chain CDR1, CDR2 and CDR3 amino acid sequences comprising the amino acid sequences of SEQ ID NOs: 4(MPF), 5(GASSRAT) and 6(MRGRPP), respectively.
